Stem cell therapy for diabetes mellitus

In this review, we present (1) a brief discussion of hematopoietic stem cell transplantation (HSCT) for severe and refractory autoimmune diseases (AIDs) from its beginning in 1996 through recently initiated prospective randomized clinical trials; (2) an update (up to July 2009) of clinical and labor...

Descripción completa

Detalles Bibliográficos
Autores principales: Voltarelli, Júlio C, Couri, Carlos E B, Oliveira, Maria C, Moraes, Daniela A, Stracieri, Ana B P L, Pieroni, Fabiano, Barros, George M N, Malmegrim, Kelen C R, Simões, Belinda P, Leal, Angela M O, Foss, Milton C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089753/
https://www.ncbi.nlm.nih.gov/pubmed/25018908
http://dx.doi.org/10.1038/kisup.2011.22
Descripción
Sumario:In this review, we present (1) a brief discussion of hematopoietic stem cell transplantation (HSCT) for severe and refractory autoimmune diseases (AIDs) from its beginning in 1996 through recently initiated prospective randomized clinical trials; (2) an update (up to July 2009) of clinical and laboratory outcomes of 23 patients with newly diagnosed type 1 diabetes mellitus (T1DM), who underwent autologous HSCT at the Bone Marrow Transplantation Unit of the Ribeirão Preto Medical School, University of São Paulo, Brazil; (3) a discussion of possible mechanisms of action of HSCT in AIDs, including preliminary laboratory data obtained from our patients; and (4) a discussion of future perspectives of stem cell therapy for T1DM and type 2 DM, including the use of stem cell sources other than adult bone marrow and the combination of cell therapy with regenerative compounds.

Ejemplares similares